Overview

This text addresses questions such as: is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit?; why have clinicians and nephrologists permitted health insurance companies and the government decide when anaemia therapy should begin in persons with progressive kidney failure?; is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin?; are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment?; when does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting?; is darbepoetin alfa, a long-acting erythropoietin, really superior to recombinant erythropoietin?

Full Product Details

Author:   Onyekachi Ifudu
Publisher:   Springer-Verlag New York Inc.
Imprint:   Springer-Verlag New York Inc.
Edition:   2002 ed.
Dimensions:   Width: 15.50cm , Height: 1.10cm , Length: 23.50cm
Weight:   0.900kg
ISBN:  

9781402006784

ISBN 10:   1402006780
Pages:   145
Publication Date:   31 July 2002
Audience:   College/higher education ,  Professional and scholarly ,  Postgraduate, Research & Scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print  
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

1. Correcting anemia slows renal disease progression.- 2. Does treatment with EPO improve RBC survival?.- 3. Has the best route of administration for epoetin been established?.- 4. Is renal anemia management determined by science or reimbursement regulations?.- 5. When does anemia impact the heart in chronic kidney disease?.- 6. Improvements in anemia management with darbepoetin alfa, a new erythropoiesis stimulating protein.- 7. Normalizing hematocrit in renal failure: dangerous or desirable?.- 8. Do race, gender or mode of dialysis modulate erythropoietin response?.- 9. Are uremic inhibitors of erythropoiesis clinically relevant?.- 10. Do ACE inhibitors limit response to EPO and should EPO be continued in patients with sepsis or fever?.- 11. Is secondary hyperparathyroidism a significant cause of renal anemia?.- 12. Is long-term intravenous iron therapy risky?.- 13. Anemia and erythropoietin therapy in kidney transplant recipients: where are the data?.- 14. Intravenous iron treatment: a comparison of available drugs.- Epilogue.

Reviews

Author Information

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions